This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Contents of /news/34.html

Parent Directory Parent Directory | Revision Log Revision Log

Revision - (show annotations) (vendor branch)
Sat Feb 3 20:19:15 2001 UTC (19 years, 8 months ago) by dpavlin
Branch: MAIN, dbp
CVS Tags: alpha, HEAD
Changes since 1.1: +0 -0 lines
File MIME type: text/html

1 <p align="center"><font face="Arial" size="2" color="#000080"><b><br>
2 PLIVA d.d. General Assembly Held Today</b></font></p>
3 <p align="justify"><font face="Arial" size="2" color="#000080">Zagreb, 8 June
4 2000 - the General Assembly of PLIVA d.d. shareholders was held today. The
5 PLIVA Management Board presented Company's 1999 operations and position,
6 while the Supervisory Board gave a presentation on their monitoring of the
7 Company's management of affairs.</font></p>
8 <p align="justify"><font face="Arial" size="2" color="#000080">PLIVA's strong expansion
9 persisted throughout 1999. Compared with 1998, revenues rose by 16.9 % to
10 HRK 4,180.5 m., of which 65.5 % were recorded on international markets.
11 Earnings before interest and taxes (EBIT) recorded a 27.3% growth to HRK
12 1,079.4 m., and the Company's net profit reached HRK 869 m. Profit per
13 share was up 27.8% to HRK 44.17.<br>
14 PLIVA furthered its internationalization with the acquisitions of three
15 pharmaceutical companies: FARMACOM, MIXIS Genetics and LACHEMA, thereby
16 reinforcing PLIVA's position in its target markets. The year 1999 was also
17 marked by strong investments and a 46.5 percent growth in R&amp;D
18 spending.</font></p>
19 <p align="justify"><font face="Arial" size="2" color="#000080">The following distribution
20 of 1999 net income (HRK 838.5 m.) was proposed in the General Assembly
21 agenda:</font></p>
22 <ul>
23 <li>
24 <p align="justify"><font face="Arial" size="2" color="#000080">HRK 2.3 m. to legal
25 reserves,</font></li>
26 <li>
27 <p align="justify"><font face="Arial" size="2" color="#000080">a declared dividend of
28 HRK 10.00 per share to be paid out to all shareholders registered with
29 the Central Depository Agency on the decision date (to be paid out
30 before 31 December 2000). The HRK 10.00 dividend per share represents
31 a 36.1% increase over last year's dividend.</font></li>
32 <li>
33 <p align="justify"><font face="Arial" size="2" color="#000080">the remainder of the
34 income to be transferred to retained earnings.</font></li>
35 </ul>
36 <p align="justify"><font face="Arial" size="2" color="#000080">Commenting on the 1999
37 business results, Mr. Zeljko Covic, President of PLIVA's Management Board,
38 said: &quot;PLIVA has retained its position as the leading CEE and largest
39 Croatian pharmaceutical company. The cornerstone of PLIVA's business
40 orientation, as well as its future, resides in its business policy of
41 continuous global market growth and development, the strategic focus on
42 pharmaceuticals, an increase in share capital value, consistent
43 investments in state-of-the-art technology and new product research &amp;
44 development&quot;.</font></p>
45 <p><font face="Arial" size="2" color="#000080"><i>PLIVA d.d. Management
46 Board members are:</i><b><br>
47 </b><br>
48 <b>Zeljko Covic</b>, MSc, President &amp; CEO<br>
49 <b>Erika Kaspar</b>, MSc, Vice-President &amp; Director of Corporate
50 Affairs and<br>
51 Communications<br>
52 <b>Radan Spaventi</b>, MD, PhD, Vice-President &amp; CSO<br>
53 <b>Dubravko Mak</b>, Vice-President &amp; COO<br>
54 <b>Zeljko Peric</b>, Vice-President &amp; CFO<br>
55 <br>
56 <br>
57 <i>PLIVA d.d. Supervisory Board members are:</i><b><br>
58 </b><br>
59 <b>Massimo Armanini</b>, MBA, President of the Supervisory Board,
61 <b>Branko Jeren</b>, PhD, Vice-President of the Supervisory Board,
62 University of Zagreb<br>
63 <b>Zdenko Adrovic</b>, Raiffeisenbank Austria d.d.<br>
64 <b>David Bloom</b>, PhD, David Bloom and Associates<br>
65 <b>Ettore dell'Isola</b>, PhD, MBA, European Vinyls Corporation<br>
66 <b>Lindsay M. Forbes</b>, MBA, EBRD<br>
67 <b>Franjo Lukovic</b>, Zagrebacka Banka d.d.<br>
68 <b>Ivan Mijatovic</b>, Ministry of Finance, Croatia<br>
69 <b>Mr. Martin Pastuovic</b>, PLIVA d.d.</font></p>
70 <p align="center"><font face="Arial" size="2" color="#000080"><b>PLIVA
72 as at 8 June 2000<br>
73 <br>
74 <br>
75 <img border="0" src="../images/SkupstinaChart.gif" width="400" height="345"></b></font></p>
76 <p align="left"><font face="Arial" size="2" color="#000080"><br>
77 For further information, please contact:</font></p>
78 <table border="0" cellpadding="0" cellspacing="0" width="100%">
79 <tr>
80 <td width="50%" valign="top" align="left"><font face="Arial" size="2" color="#000080"><b>Ms.
81 Dijana Kobas</b><br>
82 Corporate Communications<br>
83 Phone: 01 / 61 20 852<br>
84 Fax: 01 / 61 60 358<br>
85 e-mail: <a href="mailto:Dijana.Kobas@pliva.hr">Dijana.Kobas@pliva.hr<br>
86 </a></font></td>
87 </tr>
88 </table>
89 <p align="center"><font face="Arial" size="2" color="#000080"><b>PLIVA's Vision:<br>
90 <br>
91 To be a pharmaceutical company bringing superior and innovative
92 solutions to customer needs, by competing in the global market.
93 </b></font></p>

  ViewVC Help
Powered by ViewVC 1.1.26